CiToxLAB has announced that John C. Kapeghian has joined the company as senior director of toxicology in North America (Montreal, Canada).
His experience includes thirty years in preclinical drug safety at Ciba Pharmaceuticals (now Novartis) and Charles River Laboratories.
John is a renowned regulatory toxicologist. He brings outstanding expertise to the team at CiToxLAB. His skill set includes study design and implementation, data evaluation and report review, FDA pre-IND meeting representation and briefing document preparation, as well as Investigator Brochure and IND/NDA/BLA preparation.
John has a PhD in pharmacology/toxicology and is a diplomate of the American Board of Toxicology (DABT). He was formerly head of Experimental Toxicology at Ciba Pharmaceuticals (now Novartis) and then joined Charles River Laboratories where he established and led the Navigator Scientific and Regulatory Consulting Group and Program Management Team.
As the president of Preclinical Safety Associates, he has recently collaborated with pharmaceutical and biotechnology companies worldwide to advise on programs, study design and to monitor non-clinical regulatory packages.
John is a member of the Society of Toxicology and the American College of Toxicology. He sat on the editorial board of the International Journal of Toxicology.
Over the years, he has published dozens of peer-reviewed papers and continues to be active in his areas of specialty, including biotechnology-derived therapeutics development and drug-induced hepatotoxicity.
John frequently presents his work at international scientific meetings and sponsors and organizes preclinical training workshops, including study director training.
“I am delighted that we are adding a colleague of this standing to our organization. John will make a valuable contribution to our customers’ development programs. John’s recruitment reflects the CiToxLAB policy of carefully listening to our customers’ needs,” said Dr Jean-Francois Le Bigot, chairman and CEO of the CiToxLAB Group.
“CiToxLAB will celebrate its 45th anniversary in 2014, just three years after CIT merged with LAB-Research. CiToxLAB continuously invests in new techniques to validate in vivo and in vitro models. New safety pharmacology models have been recently implemented in NHPs and minipigs. We also invested in new methods for biomarkers in genomics, flow cytometry and immunohistochemistry. The hiring of John C. Kapeghian will make our Montreal site even more attractive for our clients in North America and reflects our mission to make CiToxLAB a science-driven CRO that offers the best scientific expertise to customers,” said Dr. Le Bigot.